These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19028276)

  • 21. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
    Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy.
    Valentini V; Coco C; Minsky BD; Gambacorta MA; Cosimelli M; Bellavita R; Morganti AG; La Torre G; Trodella L; Genovesi D; Portaluri M; Maurizi-Enrici R; Barbera F; Maranzano E; Lupattelli M
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):403-12. PubMed ID: 17919844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.
    Kim TH; Chang HJ; Kim DY; Jung KH; Hong YS; Kim SY; Park JW; Oh JH; Lim SB; Choi HS; Jeong SY
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1158-65. PubMed ID: 19800178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma.
    Lagonigro MS; Tamborini E; Negri T; Staurengo S; Dagrada GP; Miselli F; Gabanti E; Greco A; Casali PG; Carbone A; Pierotti MA; Pilotti S
    J Pathol; 2006 Apr; 208(5):615-23. PubMed ID: 16470538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matrix metalloproteinase-9 expression correlated with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy.
    Unsal Kilic D; Uner A; Akyurek N; Erpolat P; Dursun A; Pak Y
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):196-203. PubMed ID: 17071013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
    Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of forceps biopsy and core needle biopsy in prediction of pathologic complete remission in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Tang JH; An X; Lin X; Gao YH; Liu GC; Kong LH; Pan ZZ; Ding PR
    Oncotarget; 2015 Oct; 6(32):33919-25. PubMed ID: 26416245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors.
    Spindler KL; Nielsen JN; Lindebjerg J; Jakobsen A
    Dis Colon Rectum; 2007 Sep; 50(9):1363-9. PubMed ID: 17661145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
    Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer.
    Debucquoy A; Haustermans K; Daemen A; Aydin S; Libbrecht L; Gevaert O; De Moor B; Tejpar S; McBride WH; Penninckx F; Scalliet P; Stroh C; Vlassak S; Sempoux C; Machiels JP
    J Clin Oncol; 2009 Jun; 27(17):2751-7. PubMed ID: 19332731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy.
    Bouzourene H; Bosman FT; Seelentag W; Matter M; Coucke P
    Cancer; 2002 Feb; 94(4):1121-30. PubMed ID: 11920483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines.
    Kawamoto T; Akisue T; Marui T; Nakatani T; Hitora T; Fujita I; Kurosaka M; Yamamoto T
    Anticancer Res; 2004; 24(5A):2675-9. PubMed ID: 15517872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
    Fjällskog ML; Lejonklou MH; Oberg KE; Eriksson BK; Janson ET
    Clin Cancer Res; 2003 Apr; 9(4):1469-73. PubMed ID: 12684421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer.
    Min BS; Choi YJ; Pyo HR; Kim H; Seong J; Chung HC; Rha SY; Kim NK
    Arch Surg; 2008 Nov; 143(11):1091-7; discussion 1097. PubMed ID: 19015468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
    Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
    Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region.
    Spindler KL; Nielsen JN; Lindebjerg J; Brandslund I; Jakobsen A
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):500-4. PubMed ID: 16757132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Downstaging after chemoradiotherapy for locally advanced rectal cancer: is there more (tumor) than meets the eye?
    Mignanelli ED; de Campos-Lobato LF; Stocchi L; Lavery IC; Dietz DW
    Dis Colon Rectum; 2010 Mar; 53(3):251-6. PubMed ID: 20173469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biopsy specimens obtained 7 days after starting chemoradiotherapy (CRT) provide reliable predictors of response to CRT for rectal cancer.
    Suzuki T; Sadahiro S; Tanaka A; Okada K; Kamata H; Kamijo A; Murayama C; Akiba T; Kawada S
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1232-8. PubMed ID: 23158058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer.
    Kim DY; Jung KH; Kim TH; Kim DW; Chang HJ; Jeong JY; Kim YH; Son SH; Yun T; Hong CW; Sohn DK; Lim SB; Choi HS; Jeong SY; Park JG
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):378-84. PubMed ID: 17097835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.